Long-acting injectable HIV prevention for breastfeeding new mothers
Official title: Linking HIV Prevention and post-partum care: Safety, efficacy and feasibility of cabotegravir-LA PrEP in high-risk breastfeeding population in Botswana
Funded at Beth Israel Deaconess Medical Center · NIH-10907762 · Data updated 2026-11-12
This project looks at whether a long-acting injectable HIV prevention shot (cabotegravir) given after childbirth can safely protect breastfeeding women at high risk of HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 24, 2021 |
| Project end | August 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $221,794 |
| NIH project number | 5R01HD108047-04 |
| Project ID | NIH-10907762 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are postpartum breastfeeding women in the study area of Botswana who are at increased risk of acquiring HIV and can attend local follow-up visits.
✕Less likely to help
Women who are not breastfeeding, not at elevated HIV risk, or unable to attend the study clinics are unlikely to benefit from this specific program.
What this research studies
You would be offered a long-acting injectable called cabotegravir (CAB-LA) soon after giving birth and invited to return for follow-up visits that are provided alongside your baby's care. The team will track your health and your baby's health while you breastfeed to watch for side effects and any HIV infections. The work focuses on high-risk postpartum women in Botswana and tests whether starting CAB-LA in the hospital and linking follow-up with pediatric visits makes prevention easier to access. The study combines clinical visits, safety monitoring, and ongoing follow-up to learn if this approach is feasible and safe for breastfeeding mothers.
Why it matters
Potential benefit: If successful, this approach could reduce HIV infections in postpartum breastfeeding women and help prevent HIV in their infants.
How similar studies have gone: Large trials have shown cabotegravir injections prevent HIV better than daily oral PrEP in women, but data on safety during breastfeeding remain limited.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Zash, Rebecca Marie — Beth Israel Deaconess Medical Center
- Study coordinator: Zash, Rebecca Marie
Related research
Other NIH-funded projects on the same topics.
-
CAB-LA PrEP for breastfeeding women after delivery in Botswana
This study tests a long-acting HIV prevention shot for new mothers who are breastfeeding in Botswana to see if it prevents HIV safely and effectively.
-
CAB-LA PrEP for new mothers: safer HIV prevention for breastfeeding women in Botswana
A study tests a long-acting HIV prevention injection for breastfeeding women who are at high risk of HIV in Botswana.
-
Long-acting injectable HIV prevention for breastfeeding mothers
This project offers long-acting injectable cabotegravir to high-risk breastfeeding women starting at delivery, with follow-up through post-partum and baby-care clinics to prevent HIV.
-
Exploring a new HIV prevention method for breastfeeding women in Botswana
This study is looking at a long-lasting injectable HIV prevention medication for breastfeeding women in Botswana to see if it’s safe and helps them stay protected from HIV while making it easier to get the care they need after having a baby.
-
Harnessing male peer networks to boost HIV testing and PrEP use
A large clinical trial in South Africa tests whether giving HIV self-test kits through male peer networks, with phone support, increases PrEP uptake among men.
-
Harnessing men's peer networks to boost HIV self-testing and PrEP use
A large project in South Africa tests whether giving HIV self-test kits through men’s social networks, with phone support, can lead to more men starting PrEP and using HIV testing.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.